Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2011, Article ID 274628, 8 pages
Review Article

What Role for Angiogenesis in Childhood Acute Lymphoblastic Leukaemia?

1Laboratoire MERCI-EA3829, Rouen University, 22 rue Gambetta, 76000 Rouen, France
2Pediatric Hematology and Oncology, Rouen University Hospital, CHU Charles Nicolle, 1 rue de Germont, 76000 Rouen, France

Received 21 July 2011; Accepted 15 September 2011

Academic Editor: Domenico Ribatti

Copyright © 2011 P. Schneider et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The role of angiogenesis in acute leukaemia has been discussed since the cloning of the gene of vascular endothelial growth factor (VEGF) from the acute myelogenous leukemia cell line (HL60) and, thereafter, when the first studies reported increased bone marrow vascularity and elevation of angiogenic cytokines in acute lymphoblastic leukaemia (ALL). VEGF and basic fibroblast growth factor (bFGF) are the major proangiogenic cytokines that have been studied, and evaluation of their prognostic impact in childhood ALL has been reported in several studies, though with controversial results. The antiangiogenic response, contributing to the angiogenic balance, has scarcely been reported. The origin of the factors, their prognostic value, and their relevance as good markers of what really happens in the bone marrow are discussed in this paper. The place of antiangiogenic drugs in ALL has to be defined in the global treatment strategy.